In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

Authors
Publication date
Publisher
'Springer Science and Business Media LLC'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1038%2Fbcj.2017.87
      Last time updated on 01/04/2019